Gadobenate dimeglumine
Multihance (gadobenate dimeglumine) is a small molecule pharmaceutical. Gadobenate dimeglumine was first approved as Multihance on 2004-11-23.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Multihance, Multihance multipack
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| multihance | New Drug Application | 2021-10-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
Clinical
Clinical Trials
397 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | 7 | 3 | 9 | 22 | 9 | 48 | |
| Pain | D010146 | EFO_0003843 | R52 | 2 | 3 | 5 | 14 | 10 | 32 |
| Healthy volunteers/patients | — | 10 | — | 1 | 1 | 7 | 19 | ||
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 1 | 4 | 7 | 5 | 2 | 19 |
| Sleep initiation and maintenance disorders | D007319 | F51.01 | 1 | 4 | 8 | 1 | 1 | 15 | |
| Hot flashes | D019584 | — | 2 | 7 | 1 | 4 | 14 | ||
| Neuralgia | D009437 | EFO_0009430 | 1 | 4 | 1 | 3 | 4 | 13 | |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 3 | 1 | 8 | — | 12 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 8 | 3 | 1 | 1 | 11 |
| Chronic pain | D059350 | HP_0012532 | — | 4 | 3 | 1 | 2 | 10 |
Show 73 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 4 | — | 3 | 8 |
| Neoplasms | D009369 | C80 | — | 2 | 1 | — | 2 | 5 | |
| Depression | D003863 | F33.9 | — | 1 | 1 | — | 2 | 4 | |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 2 | — | 2 | 4 |
| Pruritus | D011537 | HP_0000989 | L29 | 1 | — | 1 | — | 2 | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 2 | 1 | — | — | 3 |
| Postoperative complications | D011183 | — | 1 | 1 | — | 1 | 3 | ||
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | 3 | — | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | 1 | 3 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | 1 | — | 1 | 3 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | — | — | 3 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | 1 | 2 |
| Psychotic disorders | D011618 | F20.81 | 1 | 2 | — | — | — | 2 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
| Male breast neoplasms | D018567 | — | 1 | — | — | — | 1 | ||
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 1 | — | — | — | 1 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 1 | — | — | — | 1 |
| Fabry disease | D000795 | E75.21 | — | 1 | — | — | — | 1 | |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | 1 | — | — | — | 1 |
Show 16 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Weight loss | D015431 | HP_0001824 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vulvodynia | D056650 | N94.81 | — | — | — | — | 2 | 2 | |
| Renal cell carcinoma | D002292 | — | — | — | — | 2 | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 2 | 2 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
| Pelvic neoplasms | D010386 | — | — | — | — | 2 | 2 | ||
| Aortic valve disease | D000082862 | — | — | — | — | 1 | 1 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | — | 1 | 1 | |
| Spinal fusion | D013123 | — | — | — | — | 1 | 1 | ||
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
Show 26 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GADOBENATE DIMEGLUMINE |
| INN | gadobenic acid |
| Description | Gadobenic acid (INN, brand name Multihance) is a complex of gadolinium with the ligand BOPTA. In the form of the methylglucamine salt meglumine gadobenate (INNm) or gadobenate dimeglumine (USAN), it is used as a gadolinium-based MRI contrast medium.
|
| Classification | Small molecule |
| Drug class | gadolinium derivatives (principally for diagnostic use) |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C([O-])CN(CCN(CCN(CC(=O)O)C(COCc1ccccc1)C(=O)[O-])CC(=O)O)CC(=O)[O-].[Gd+3] |
Identifiers
| PDB | — |
| CAS-ID | 113662-23-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200571 |
| ChEBI ID | — |
| PubChem CID | 9852779 |
| DrugBank | DB00743 |
| UNII ID | 15G12L5X8K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,764 documents
View more details
Safety
Black-box Warning
Black-box warning for: Multihance
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,516 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more